Immunotherapy, which is used in cancer treatment to block the immune checkpoints such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1), has shown promising outcomes in advanced cancers. This evidence concerns the gene PDCD1 and cancer.